

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

VOLUNTARY ANNOUNCEMENT
INVESTIGATIONAL NEW DRUG APPROVAL FOR INNOVATIVE DRUG
SKB518 FOR INJECTION BY THE NATIONAL MEDICAL PRODUCTS
ADMINISTRATION

The board (the “**Board**”) of directors (“**Directors**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) is pleased to announce that the Company has received a clinical trial notice approving the investigational new drug application for the innovative drug SKB518 for injection developed by the Company from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on June 17, 2024.

SKB518 for injection is a novel ADC drug with proprietary intellectual property rights developed by the Company based on the biological characteristics of the target and using the technology of the “OptiDC™” platform, which has demonstrated promising efficacy and safety window in preclinical studies and is intended to be used for the treatment of advanced solid tumors.

In accordance with the clinical trial notice issued by the NMPA, the Company plans to organize and implement a clinical trial of SKB518 for injection.

RISK WARNING

SKB518 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY’S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, June 17, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.